The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Highlights in CLL at ASH and future research
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines key abstracts in the field of chronic lymphocytic leukemia (CLL) presented at ASH 2020. Dr Jain discusses how a trial of LOXO305 (NCT03740529) has shown good efficacy and how the CLL14 trial (NCT02242942) of a venetoclax combination in both front-line and relapsed/refractory settings has demonstrated durable remissions. Furthermore, Dr Jain describes a variety of interesting abstracts on chimeric antigen receptor (CAR) T-cell therapy, highlighting the high efficacy of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Nitin Jain, MD, has received research funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Aprea Therapeutics and Fate Therapeutics; and has participated in advisory boards or received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier, Precision Biosciences, Beigene, TG Therapeutics and ADC Therapeutics.
